- Home
- ZIP vs INBX Comparison
ZIP vs INBX Comparison
Compare ZIP & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZIP
- INBX
- Stock Information
- Founded
- ZIP 2010
- INBX 2010
- Country
- ZIP United States
- INBX United States
- Employees
- ZIP N/A
- INBX N/A
- Industry
- ZIP Diversified Commercial Services
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- ZIP Consumer Discretionary
- INBX Health Care
- Exchange
- ZIP Nasdaq
- INBX Nasdaq
- Market Cap
- ZIP 427.4M
- INBX 430.2M
- IPO Year
- ZIP 2021
- INBX 2020
- Fundamental
- Price
- ZIP $3.97
- INBX $33.88
- Analyst Decision
- ZIP Hold
- INBX Hold
- Analyst Count
- ZIP 4
- INBX 2
- Target Price
- ZIP $4.75
- INBX N/A
- AVG Volume (30 Days)
- ZIP 864.5K
- INBX 123.8K
- Earning Date
- ZIP 11-05-2025
- INBX 11-13-2025
- Dividend Yield
- ZIP N/A
- INBX N/A
- EPS Growth
- ZIP N/A
- INBX N/A
- EPS
- ZIP N/A
- INBX N/A
- Revenue
- ZIP $450,401,000.00
- INBX $1,400,000.00
- Revenue This Year
- ZIP N/A
- INBX $563.00
- Revenue Next Year
- ZIP $9.96
- INBX $230.77
- P/E Ratio
- ZIP N/A
- INBX N/A
- Revenue Growth
- ZIP N/A
- INBX N/A
- 52 Week Low
- ZIP $3.35
- INBX $10.81
- 52 Week High
- ZIP $11.25
- INBX $37.53
- Technical
- Relative Strength Index (RSI)
- ZIP 30.83
- INBX 70.20
- Support Level
- ZIP $3.97
- INBX $31.75
- Resistance Level
- ZIP $4.36
- INBX $37.53
- Average True Range (ATR)
- ZIP 0.27
- INBX 1.99
- MACD
- ZIP -0.11
- INBX 0.27
- Stochastic Oscillator
- ZIP 3.08
- INBX 67.38
About ZIP ZipRecruiter Inc.
ZipRecruiter Inc is an online employment marketplace. It connects millions of job seekers with companies of all sizes. It is a two-sided marketplace for work that simplifies the job market for both job seekers and employers. Unlike traditional online job sites, ZipRecruiter works like a matchmaker curating job opportunities for job seekers, and candidates for employers.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.